Clinical Trials Directory

Trials / Unknown

UnknownNCT02407106

Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children

Efficacy of Streptococcus Salivarius BLIS (Bacteriocin-like Inhibitory Substance) K12 as Preventive Measure for Rheumatic Children.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Kaplan Medical Center · Academic / Other
Sex
All
Age
6 Years – 16 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether daily treatment with Streptococcus Salivarius BLIS K-12 prevents streptococcal throat infection in children that have had an episode of rheumatic fever.

Detailed description

Children diagnosed with Rheumatic fever are currently given preventive streptococcal treatment with either monthly IM (intramuscular injection) Penicillin or daily oral Penicillin. This preventive treatment is recommended for years until the child is 20 y old or even later. The compliance rate for this treatment declines significantly with time (the injections are painful) and even with good adherence the prevention is not complete. In the last few years a new product licensed as "BLIS K-12" has been developed and approved by FDA as GRAS (generally recognized as safe) status from 2011. This probiotic treatment prevents the pathogenic Strep A from adhering to the throat of the child thus preventing the infection. This kind of prevention is better for the long run for the patient and for the surrounding, It is better tolerated, is effective even if a dose is skipped or missed is not painful and is tasty to the children. So the investigators assumption is that giving this product to children instead of Penicillin either orally or intramuscularlly will be better tolerated thus give a better protection profile with much less side effects. The investigators will be giving BLIS K-12 to those children on the trial on a daily basis for 6 autumn-winter months instead of Penicillin and will monitor the children by monthly throat swabs. The investigators will also obtain Anti Streptolysin blood test at the end of the period from all participants to evaluate possible Strep encounters.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTStreptococcus Salivarius BLIS K12Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.

Timeline

Start date
2015-09-01
Primary completion
2016-03-01
First posted
2015-04-02
Last updated
2015-04-03

Source: ClinicalTrials.gov record NCT02407106. Inclusion in this directory is not an endorsement.